Publicaciones iLUNG

Publicaciones iLUNG 2020

Publicaciones iLUNG 2019

Publicaciones iLUNG 2018

Jose González-Martínez, Andrzej Cwersch, Diego Martinez-Alonso, Luis R Lopez, Jorge Almagro, Diego Megías, Jasminka Boskovic, Javier Gilabert, Osvaldo Graña Castro, Alessandra Pierani, Axel Behrens, Sagrario Ortega, Marcos Malumbres (2020) Lack of adaptation to centriolar defects leads to p53-independent microcephaly in the absence of Cep135.  https://doi.org/10.1101/2020.05.07.082032 [Full text]

López-Ríos F, Paz-Ares L, Sanz J, Isla D, Pijuan L, Felip E, Gómez-Román JJ, de Castro J, Conde E, Garrido P. (2020) [Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology]. Rev Esp Patol. 53. 167-18. [PMID: 32650968]

Salazar-Roa M, Trakala M, Álvarez-Fernández M, Valdés-Mora F, Zhong C, Muñoz J, Yu Y, Peters TJ, Graña-Castro O, Serrano R, Zapatero-Solana E, Abad M, Bueno MJ, de Cedrón MG, Fernández-Piqueras J, Serrano M, Blasco MA, Wang DZ, Clark SJ, Izpisua-Belmonte JC, Ortega S, Malumbres M. (2020) Transient exposure to miR-203 enhances the differentiation capacity of established pluripotent stem cells. EMBO J. doi: 10.15252/embj.2019104324. [PMID: 32614092]

Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Parra HS, Mazières J, Hermes B, Cicin I, Medgyasszay B, Cid JR, Okamoto I, Lee S, Ramlau R, Vladimirov V, Cheng Y, Deng X, Zhang Y, Bas T, Piperdi B, Halmos B. (2020) A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407. J Thorac Oncol. doi: 10.1016/j.jtho.2020.06.015. [PMID: 32599071]

Yarza R, Bover M, Paredes D, López-López F, Jara-Casas D, Castelo-Loureiro A, Baena J, Mazarico JM, Folgueira MD, Meléndez-Carmona MÁ, Reyes A, Lumbreras C, Paz-Ares L, Díaz-Pedroche C, Gómez-Martín C. (2020) SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death. Eur J Cancer. doi: 10.1016/j.ejca.2020.06.001. [PMID: 32586724]

Manso L, De Velasco G, Paz-Ares L. (2020) Impact of the COVID-19 outbreak on cancer patient flow and management: experience from a large university hospital in Spain. ESMO Open. doi: 10.1136/esmoopen-2020-000828. [PMID: 32571808]

Moreira AL, Ocampo PS, Xia Y, Zhong H, Russell PA, Minami Y, Cooper WA, Yoshida A, Bubendorf L, Papotti M, Pelosi G, Lopez-Rios F, Kunitoki K, Ferrari-Light D, Sholl LM, Beasley MB, Borczuk A, Botling J, Brambilla E, Chen G, Chou TY, Chung JH, Dacic S, Jain D, Hirsch FR, Hwang D, Lantuejoul S, Lin D, Longshore JW, Motoi N, Noguchi M, Poleri C, Rekhtman N, Tsao MS, Thunnissen E, Travis WD, Yatabe Y, Roden AC, Daigneault JB, Wistuba II, Kerr KM, Pass H, Nicholson AG, Mino-Kenudson M. (2020) A Grading system for invasive pulmonary adenocarcinoma: a proposal from the IASLC pathology committee. J Thorac Oncol. doi: 10.1016/j.jtho.2020.06.001. [PMID: 32562873]

Martins FC, Couturier DL, Paterson A, Karnezis AN, Chow C, Nazeran TM, Odunsi A, Gentry-Maharaj A, Vrvilo A, Hein A, Talhouk A, Osorio A, Hartkopf AD, Brooks-Wilson A, DeFazio A, Fischer A, Hartmann A, Hernandez BY, McCauley BM, Karpinskyj C, de Sousa CB, Høgdall C, Tiezzi DG, Herpel E, Taran FA, Modugno F, Keeney G, Nelson G, Steed H, Song H, Luk H, Benitez J, Alsop J, Koziak JM, Lester J, Rothstein JH, de Andrade JM, Lundvall L, Paz-Ares L, Robles-Díaz L, Wilkens LR, Garcia MJ, Intermaggio MP, Alcaraz ML, Brett MA, Beckmann MW, Jimenez-Linan M, Anglesio M, Carney ME, Schneider M, Traficante N, Pejovic N, Singh N, Le N, Sinn P, Ghatage P, Erber R, Edwards R, Vierkant R, Ness RB, Leung S, Orsulic S, Brucker SY, Kaufmann SH, Fereday S, Gayther S, Winham SJ, Kommoss S, Pejovic T, Longacre TA, McGuire V, Rhenius V, Sieh W, Shvetsov YB, Whittemore AS, Staebler A, Karlan BY, Rodriguez-Antona C, Bowtell DD, Goode EL, Høgdall E, Candido Dos Reis FJ, Gronwald J, Chang-Claude J, Moysich KB, Kelemen LE, Cook LS, Goodman MT, Fasching PA, Crawford R, Deen S, Menon U, Huntsman DG, Köbel M, Ramus SJ, Pharoah PDP, Brenton JD. (2020) Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. Br J Cancer. doi: 10.1038/s41416-020-0900-0. [PMID: 32555365]

Sholl LM, Hirsch FR, Hwang D, Botling J, Lopez-Rios F, Bubendorf L, Mino-Kenudson M, Roden AC, Beasley MB, Borczuk A, Brambilla E, Chen G, Chou TY, Chung JH, Cooper WA, Dacic S, Lantuejoul S, Jain D, Lin D, Minami Y, Moreira A, Nicholson AG, Noguchi M, Papotti M, Pelosi G, Poleri C, Rekhtman N, Sound-Tsao M, Thunnissen E, Travis W, Yatabe Y, Yoshida A, Daigneault JB, Zehir A, Peters S, Wistuba II, Kerr KM, Longshore JW. (2020) Tumor Mutation Burden: Promises and Challenges A Perspective from the IASLC Pathology Committee. J Thorac Oncol. doi: 10.1016/j.jtho.2020.05.019. [PMID: 32522712]

Früh M, Panje CM, Reck M, Blackhall F, Califano R, Cappuzzo F, Besse B, Novello S, Garrido P, Felip E, O’Brien M, Paz Ares L, de Marinis F, Westeel V, De Ruysscher D, Putora PM. (2020) Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) – A decision-making analysis amongst European lung cancer experts. Lung Cancer 146, 6-11. [PMID: 32485661]

Gosney JR, Hofman P, Troncone G, Lopez-Rios F. (2020) Cellular pathology in the COVID-19 era: a European perspective on maintaining quality and safety. J Clin Pathol, doi: 10.1136/jclinpath-2020-206789. [PMID: 32482888]

Putora PM, Fischer GF, Früh M, Califano R, Faivre-Finn C, Van Houtte P, McDonald F, Nestle U, Dziadziuszko R, Le Pechoux C, Ramella S, Belderbos J, Slotman BJ, Troost EGC, Peeters S, Widder J, Pöttgen C, Reck M, Blackhall F, Cappuzzo F, Besse B, Novello S, Garrido P, Felip E, O’Brien M, Paz Ares L, de Marinis F, Westeel V, De Ruysscher D. (2020) Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts. Radiother Oncol. 149, 84-88. [PMID: 32445987]

Rolfo C, Cardona AF, Cristofanilli M, Paz-Ares L, Diaz Mochon JJ, Duran I, Raez LE, Russo A, Lorente JA, Malapelle U, Gil-Bazo I, Jantus-Lewintre E, Pauwels P, Mok T, Serrano MJ; ISLB. (2020) Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). Crit Rev Oncol Hematol. 151, 102978. [PMID: 32428812]

Martínez-Alonso D, Malumbres M. (2020) Mammalian cell cycle cyclins. Semin Cell Dev Biol. doi: 10.1016/j.semcdb.2020.03.009. [PMID: 32334991]

Drosten M, Barbacid M. (2020) Targeting the MAPK Pathway in KRAS-Driven Tumors. Cancer Cell 37, 543-550. [PMID: 32289276]

Álvarez-Fernández M, Malumbres M. (2020) Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition. Cancer Cell 37, 514-529. [PMID: 32289274]

Gil-Santos E, Ruz JJ, Malvar O, Favero I, Lemaître A, Kosaka PM, García-López S, Calleja M, Tamayo J. (2020) Optomechanical detection of vibration modes of a single bacterium. Nat Nanotechnol. doi: 10.1038/s41565-020-0672-y. [PMID: 32284570]

Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, Peters S, Ponce S, Fernández C, Alfaro V, Gómez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Martínez M, Delord JP, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D’Arcangelo M, Santoro A, Villalobos VM, Sands J, Paz-Ares L. (2020) Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 21, 645-654. [PMID: 32224306]

Molina J, Ramos D, Gil-Santos E, Escobar JE, Ruz JJ, Tamayo J, San Paulo A, Calleja M. (2020) Optical transduction for vertical nanowire resonators. Nano Lett. doi: 10.1021/acs.nanolett.9b04909. [PMID: 32191041]

Remon J, Passiglia F, Ahn MJ, Barlesi F, Forde PM, Garon EB, Gettinger S, Goldberg SB, Herbst RS, Horn L, Kubota K, Lu S, Mezquita L, Paz-Ares L, Popat S, Schalper KA, Skoulidis F, Reck M, Adjei AA, Scagliotti GV. (2020) Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations. J Thorac Oncol. doi: 10.1016/j.jtho.2020.03.006. [PMID: 32179179]

Paz-Ares L, Kim TM, Vicente D, Felip E, Lee DH, Lee KH, Lin CC, Flor MJ, Di Nicola M, Alvarez RM, Dussault I, Helwig C, Ojalvo LS, Gulley JL, Cho BC. (2020) Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in second-line treatment of patients with non-small cell lung cancer: results from an expansion cohort of a phase 1 trial. J Thorac Oncol. doi: 10.1016/j.jtho.2020.03.003. [PMID: 32173464]

Mazarico Gallego JM, Herrera Juárez M, Paz-Ares L. (2020) The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer. Expert Opin Drug Saf. doi: 10.1080/14740338.2020.1736554. [PMID: 32129104]

Quintanal-Villalonga Á, Ferrer I, Guruceaga E, Cirauqui C, Marrugal Á, Ojeda L, García S, Zugazagoitia J, Muñoz-Galván S, Lopez-Rios F, Montuenga L, Vicent S, Molina-Pinelo S, Carnero A, Paz-Ares L. (2020) FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy. EBioMedicine 53: 102683. [PMID: 32114392]

Salvador-Barbero B, Álvarez-Fernández M, Zapatero-Solana E, El Bakkali A, Menéndez MDC, López-Casas PP, Di Domenico T, Xie T, VanArsdale T, Shields DJ, Hidalgo M, Malumbres M. (2020) CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. Cancer Cell doi: 10.1016/j.ccell.2020.01.007. [PMID: 32109375]

Sanz-Gómez N, de Pedro I, Ortigosa B, Santamaría D, Malumbres M, de Cárcer G, Gandarillas A. (2020) Squamous differentiation requires G2/mitosis slippage to avoid apoptosis. Cell Death Differ. doi: 10.1038/s41418-020-0515-2. [PMID: 32080348]

Felip E, Ardizzoni A, Ciuleanu T, Cobo M, Laktionov K, Szilasi M, Califano R, Carcereny E, Griffiths R, Paz-Ares L, Duchnowska R, Garcia MA, Isla D, Jassem J, Appel W, Milanowski J, Van Meerbeeck JP, Wolf J, Li A, Acevedo A, Popat S. (2020) CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. Eur J Cancer 127, 160-172. [PMID: 32028209]

Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y. (2020) IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens following neoadjuvant therapy. J Thorac Oncol. doi: 10.1016/j.jtho.2020.01.005. [PMID: 32004713]

Vitos-Faleato J, Real SM, Gutierrez-Prat N, Villanueva A, Llonch E, Drosten M, Barbacid M, Nebreda AR. (2020) Requirement for epithelial p38α in KRAS-driven lung tumor progression. Proc Natl Acad Sci USA. doi: 10.1073/pnas.1921404117. [PMID: 31969449]

Cedrés S, Ponce-Aix S, Iranzo P, Callejo A, Pardo N, Navarro A, Martinez-Marti A, Gómez-Abecia S, Zucchiatti AC, Sansano I, Enguita AB, Miquel JM, Viaplana C, Dienstmann R, Paz-Ares L, Felip E. (2020) Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients. Clin Transl Oncol. doi: 10.1007/s12094-019-02275-9. [PMID: 31916017]

Hermida, D., Mortuza, G.B., Pedersen, A.K., Pozdnyakova, I., Nguyen, T.T.T.N., Maroto, M., Williamson, M., Ebersole, T., Cazzamali, G., Rand, K., Olsen, J.V., Malumbres, M. and Montoya, G. (2020) Molecular basis of the mechanisms controlling MASTL. Mol. Cell. Proteomics 19, 326-343. [PMID: 31852836][Full text]

Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 21, 271-282. Erratum in: Lancet Oncol. 2020 Feb;21(2):e70. Lancet Oncol. 2020 Jul;21(7):e341. [PMID: 31838007]

Mazieres J, Kowalski D, Luft A, Vicente D, Tafreshi A, Gümü? M, Laktionov K, Hermes B, Cicin I, Rodríguez-Cid J, Wilson J, Kato T, Ramlau R, Novello S, Reddy S, Kopp HG, Piperdi B, Li X, Burke T, Paz-Ares L. (2020) Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer. J Clin Oncol. 38, 271-280. [PMID: 31751163]

Barbacid M. (2019) On the right TRK: from oncogene discovery to cancer therapeutics. Ann Oncol. doi: 10.1093/annonc/mdz290. [PMID: 32223936]

Garassino MC, Paz-Ares L, Hui R, Faivre-Finn C, Spira A, Planchard D, Ozguroglu M, Daniel DB, Vicente D, Murakami S, Rydén A, Zhang Y, O’Brien C, Dennis PA, Antonia SJ. (2019) Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC). Ann Oncol. 30 Suppl 2:ii78. doi: 10.1093/annonc/mdz094.001. [PMID: 32131355]

Paz-Ares L, Senan S, Planchard D, Wang L, Cheong A, Slepetis R, Nguyen MH, Vokes EE. (2019) RATIONALE 001: Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC). Ann Oncol. 30 Suppl 2:ii67. doi: 10.1093/annonc/mdz063.083. [PMID: 32131325]

Paz-Ares L, Doebele RC, Farago AF, Liu SV, Chawla SP, Tosi D, Blakely CM, Krauss JC, Sigal D, Bazhenova L, John T, Besse B, Wolf J, Seto T, Chow-Maneval E, Ye C, Simmons B, Demetri GD. (2019) Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001. Ann Oncol. 30 Suppl 2:ii48-ii49. doi: 10.1093/annonc/mdz063.011. [PMID: 32131246]

Planchard D, Garassino MC, Paz-Ares L, Faivre-Finn C, Spira A, Gu Y, Wadsworth C, Whiteley J, Scott M, Boothman AM, Ratcliffe M, Walker J, Dennis PA, Antonia SJ. (2019) Prevalence of programmed death ligand-1 (PD-L1) by demographic, disease and sample characteristics in unresectable, stage III NSCLC (PACIFIC). Ann Oncol. 30 Suppl 2:ii32-ii33. doi: 10.1093/annonc/mdz067.002. [PMID: 32131218]

Zugazagoitia J, Ramos I, Trigo JM, Palka M, Gómez-Rueda A, Jantus-Lewintre E, Camps C, Isla D, Iranzo P, Ponce-Aix S, García-Campelo R, Provencio M, Franco F, Bernabé R, Juan-Vidal O, Felip E, de Castro J, Sanchez-Torres JM, Faul I, Lanman RB, Garrido P, Paz-Ares L. (2019) Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. Ann Oncol 30, 290-296. [PMID: 31987427]

Peters S, Dafni U, Boyer M, De Ruysscher D, Faivre-Finn C, Felip E, Garrido P, Girard N, Guckenberger M, Haanen J, Le Pechoux C, Mornex F, Ozsahin M, Paz-Ares L, Planchard D, Raben D, Ramalingam S, Reck M, Smit E, Stahel R, Stenzinger A, Swanton C, Vallone S, Garassino MC. (2019) Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Ann Oncol 30, 161-165. [PMID: 31987413]

Marchiò C, Scaltriti M, Ladanyi M, Iafrate AJ, Bibeau F, Dietel M, Hechtman JF, Troiani T, López-Rios F, Douillard JY, Andrè F, Reis-Filho JS. (2019) ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol. 30, 1417-1427. [PMID: 31987396]

Lantuejoul S, Tsao MS, Cooper WA, Girard N, Hirsch FR, Roden AC, Lopez-Rios F, Jain D, Chou TY, Motoi N, Kerr KM, Yatabe Y, Brambilla E, Longshore J, Papotti M, Sholl LM, Thunnissen E, Rekhtman N, Borczuk A, Bubendorf L, Minami Y, Beasley MB, Botling J, Chen G, Chung JH, Dacic S, Hwang D, Lin D, Moreira A, Nicholson AG, Noguchi M, Pelosi G, Poleri C, Travis W, Yoshida A, Daigneault JB, Wistuba II, Mino-Kenudson M. (2019) PD-L1 Testing for Lung Cancer in 2019: Perspective from the IASLC Pathology Committee. J Thorac Oncol. doi: 10.1016/j.jtho.2019.12.107. [PMID: 31870882]

Munster P, Mita M, Mahipal A, Nemunaitis J, Massard C, Mikkelsen T, Cruz C, Paz-Ares L, Hidalgo M, Rathkopf D, Blumenschein G Jr, Smith DC, Eichhorst B, Cloughesy T, Filvaroff EH, Li S, Raymon H, de Haan H, Hege K, Bendell JC. (2019) First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. Cancer Manag Res. 11, 10463-10476. [PMID: 31853198]

Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. (2019) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. doi: 10.1016/S1470-2045(19)30691-6. [PMID: 31838007]

Garrido-Martín EM, Paz-Ares L. (2019) Lung Cancer and Microbiome. Arch Bronconeumol. doi: 10.1016/j.arbres.2019.04.012. [PMID: 31836241]

Agulló-Ortuño MT, García-Ruiz I, Díaz-García CV, Enguita AB, Pardo-Marqués V, Prieto-García E, Ponce S, Iglesias L, Zugazagoitia J, López-Martín JA, Paz-Ares L, Nuñez JA. (2019) Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients. Cancer Chemother Pharmacol. doi: 10.1007/s00280-019-04008-9. [PMID: 31832811]

García-Gutiérrez L, Bretones G, Molina E, Arechaga I, Symonds C, Acosta JC, Blanco R, Fernández A, Alonso L, Sicinski P, Barbacid M, Santamaría D, León J. (2019) Myc stimulates cell cycle progression through the activation of Cdk1 and phosphorylation of p27. Sci Rep. 9, 18693. [PMID: 31822694]

Martín-Pérez A, Ramos D, Gil-Santos E, García-López S, Yubero ML, Kosaka PM, San Paulo A, Tamayo J, Calleja M. (2019) Mechano-optical analysis of single cells with transparent microcapillary resonators. ACS Sens. doi: 10.1021/acssensors.9b02038. [PMID: 31782299]

Martín-Pérez A, Ramos D, Tamayo J, Calleja M. (2019) Coherent Optical Transduction of Suspended Microcapillary Resonators for Multi-Parameter Sensing Applications. Sensors 19, E5069. doi: 10.3390/s19235069. [PMID: 31757060]

Kim JW, Marquez CP, Kostyrko K, Koehne AL, Marini K, Simpson DR, Lee AG, Leung SG, Sayles LC, Shrager J, Ferrer I, Paz-Ares L, Gephart MH, Vicent S, Cochran JR, Sweet-Cordero EA. (2019) Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinoma. Nat Med. 25, 1783-1795. [PMID: 31700175]

Heinhuis KM, Carlino M, Joerger M, Di Nicola M, Meniawy T, Rottey S, Moreno V, Gazzah A, Delord JP, Paz-Ares L, Britschgi C, Schilder RJ, O’Byrne K, Curigliano G, Romano E, Patah P, Wang R, Liu Y, Bajaj G, Siu LL. (2019) Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial. JAMA Oncol. doi: 10.1001/jamaoncol.2019.3848. [PMID: 31697308]

Soldevilla B, Carretero-Puche C, Gomez-Lopez G, Al-Shahrour F, Riesco MC, Gil-Calderon B, Alvarez-Vallina L, Espinosa-Olarte P, Gomez-Esteves G, Rubio-Cuesta B, Sarmentero J, La Salvia A, Garcia-Carbonero R. (2019) The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications. Eur J Cancer 123, 118-129. [PMID: 31678770]

McClung MR, O’Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MS; LOFT Investigators. (2019) Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. Lancet Diabetes Endocrinol 7, 899-911. [PMID: 31676222]

Capdevila J, Arqués O, Hernandez Mora JR, Matito J, Caratu G, Mancuso FM, Landolfi S, Barriuso J, Jimenez-Fonseca P, Lopez Lopez C, Garcia-Carbonero R, Hernando J, Matos I, Paolo N, Hernández-Losa J, Esteller M, Martínez-Cardús A, Tabernero J, Vivancos A, Palmer HG. (2019) Epigenetic EGFR gene repression confers sensitivity to therapeutic BRAFV600E blockade in colon neuroendocrine carcinomas. Clin Cancer Res. doi: 10.1158/1078-0432.CCR-19-1266. [PMID: 31672771]

Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, Ferrer I, Giry A, Quantin X, Pujol JL, Calvayrac O, Moll HP, Glasson Y, Pirot N, Turtoi A, Cañamero M, Wong KK, Yarden Y, Casanova E, Soria JC, Colinge J, Siebel CW, Mazieres J, Favre G, Paz-Ares L, Maraver A. (2019) Notch inhibition overcomes resistance to Tyrosine Kinase Inhibitors in EGFR-driven lung adenocarcinoma. J Clin Invest. doi: 10.1172/JCI126896. [PMID: 31671073]

Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, Cho BC, Planchard D, Paz-Ares L, Faivre-Finn C, Vansteenkiste JF, Spigel DR, Wadsworth C, Taboada M, Dennis PA, Özgüroğlu M, Antonia SJ. (2019) Brief report: Three-year overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC – Update from PACIFIC. J Thorac Oncol. doi: 10.1016/j.jtho.2019.10.002. [PMID: 31622733]

Garrido P, Conde E, de Castro J, Gómez-Román JJ, Felip E, Pijuan L, Isla D, Sanz J, Paz-Ares L, López-Ríos F. (2019) Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. doi: 10.1007/s12094-019-02218-4. [PMID: 31598903]

Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. (2019) Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 1655-1669. [PMID: 31591063]

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394, 1929-1939. [PMID: 31590988]

Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O’Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. (2019) Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.  N Engl J Med. 381, 2020-2031. [PMID: 31562796]

Agulló-Ortuño MT, Gómez-Martín Ó, Ponce S, Iglesias L, Ojeda L, Ferrer I, García-Ruiz I, Paz-Ares L, Pardo-Marqués V. (2019) Blood Predictive Biomarkers for Patients With Non-small-cell Lung Cancer Associated With Clinical Response to Nivolumab. Clin Lung Cancer. doi: 10.1016/j.cllc.2019.08.006. [PMID: 31562055]

Cardone C, Martinelli E, Troiani T, Sforza V, Avallone A, Nappi A, Montesarchio V, Andreozzi F, Biglietto M, Calabrese F, Bordonaro R, Cordio S, Bregni G, Febbraro A, Garcia-Carbonero R, Feliu J, Cervantes A, Ciardiello F. (2019) Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer. ESMO Open. 4, e000519. [PMID: 31555481]

Wolin E, Mita A, Mahipal A, Meyer T, Bendell J, Nemunaitis J, Munster PN, Paz-Ares L, Filvaroff EH, Li S, Hege K, de Haan H, Mita M. (2019) A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. PLoS One 14, e0221994. [PMID: 31527867]

Huang RSP, Smith D, Le CH, Liu WW, Ordinario E, Manohar C, Lee M, Rajamani J, Truong H, Li J, Choi C, Li J, Pati A, Bubendorf L, Buettner R, Kerr KM, Lopez-Rios F, Marchetti A, Marondel I, Nicholson AG, Öz AB, Pauwels P, Penault-Llorca F, Rossi G, Thunnissen E, Newell AH, Pate G, Menzl I. (2019) Correlation of ROS1 Immunohistochemistry With <i>ROS1</i> Fusion Status Determined by Fluorescence In Situ Hybridization. Arch Pathol Lab Med. doi: 10.5858/arpa.2019-0085-OA. [PMID: 31509456]

Dingemans AC, Hendriks LEL, Berghmans T, Levy A, Hasan B, Faivre-Finn C, Giaj-Levra M, Giaj-Levra N, Girard N, Greillier L, Lantuéjoul S, Edwards J, O’Brien M, Reck M, Smit EF, Van Schil P, Postmus PE, Ramella S, Lievens Y, Gaga M, Peled N, Scagliotti GV, Senan S, Paz-Ares L, Guckenberger M, McDonald F, Ekman S, Cufer T, Gietema H, Infante M, Dziadziuszko R, Peters S, Porta RR, Vansteenkiste J, Dooms C, de Ruysscher D, Besse B, Novello S. (2019) Definition of synchronous oligo-metastatic non-small cell lung cancer – a consensus report. J Thorac Oncol. doi: 10.1016/j.jtho.2019.07.025. [PMID: 31398540]

Isla D, de Castro J, García-Campelo R, Lianes P, Felip E, Garrido P, Paz-Ares L, Trigo JM. (2019) Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus. Clin Transl Oncol. doi: 10.1007/s12094-019-02191-y. [PMID: 31368078]

Conde E, Hernandez S, Martinez R, Angulo B, De Castro J, Collazo-Lorduy A, Jimenez B, Muriel A, Mate JL, Moran T, Aranda I, Massuti B, Rojo F, Domine M, Sansano I, Garcia F, Felip E, Mancheño N, Juan O, Sanz J, Gonzalez-Larriba JL, Atienza-Cuevas L, Arriola-Arellano E, Abdulkader I, Garcia-Gonzalez J, Camacho C, Rodriguez-Abreu D, Teixido C, Reguart N, Gonzalez-Piñeiro A, Lazaro-Quintela M, Lozano MD, Gurpide A, Gomez-Roman J, Lopez-Brea M, Pijuan L, Salido M, Arriola E, Company A, Insa A, Esteban-Rodriguez I, Saiz M, Azkona E, Alvarez R, Artal A, Plaza ML, Aguiar D, Enguita AB, Benito A, Paz-Ares L, Garrido P, Lopez-Rios F. (2019) Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Non-Small Cell Lung Carcinoma Patients: the ROSING Study. J Thorac Oncol. doi: 10.1016/j.jtho.2019.07.005. [PMID: 31349061]

Carmona-Bayonas A, Jiménez-Fonseca P, Lamarca Á, Barriuso J, Castaño Á, Benavent M, Alonso V, Riesco-Martínez MDC, Alonso-Gordoa T, Custodio A, Sánchez Cánovas M, Hernando Cubero J, López C, Lacasta A, Fernández Montes A, Marazuela M, Crespo G, Escudero P, Diaz JÁ, Feliciangeli E, Gallego J, Llanos M, Segura Á, Vilardell F, Percovich JC, Grande E, Capdevila J, Valle JW, García-Carbonero R. (2019) Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study. J Clin Oncol. doi: 10.1200/JCO.19.00980. [PMID: 31390276]

Marrugal Á, Ferrer I, Pastor MD, Ojeda L, Quintanal-Villalonga Á, Carnero A, Molina-Pinelo S, Paz-Ares L. (2019) Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry. Cells 8, E806. doi: 10.3390/cells8080806. [PMID: 31370342]

Sridhar S, Paz-Ares L, Liu H, Shen K, Morehouse C, Rizvi N, Segal NH, Jin X, Zheng Y, Narwal R, Gupta A, Dennis PA, Ye J, Mukhopadhyay P, Higgs BW, Ranade K. (2019) Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients.  Clin Lung Cancer 20, e601-e608. [PMID: 31327642]

Zugazagoitia J, Gómez-Rueda A, Jantus-Lewintre E, Isla D, Camps C, Ramos I, Trigo JM, Bernabé R, Juan-Vidal O, Sanchez-Torres JM, García-Campelo R, Provencio M, Felip E, de Castro J, Faull I, Lanman RB, Ponce-Aix S, Paz-Ares L, Garrido P. (2019) Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. Lung Cancer 134, 72-78. [PMID: 31319999]

Ackermann CJ, Reck M, Paz-Ares L, Barlesi F, Califano R. (2019) First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light. Lung Cancer. 134, 245-253. [PMID: 31319988]

Olbrich T, Vega-Sendino M, Murga M, de Carcer G, Malumbres M, Ortega S, Ruiz S, Fernandez-Capetillo O. (2019) A Chemical Screen Identifies Compounds Capable of Selecting for Haploidy in Mammalian Cells. Cell Rep. 28, 597-604.e4 [PMID: 31315040]

Herbst RS, Arkenau HT, Santana-Davila R, Calvo E, Paz-Ares L, Cassier PA, Bendell J, Penel N, Krebs MG, Martin-Liberal J, Isambert N, Soriano A, Wermke M, Cultrera J, Gao L, Widau RC, Mi G, Jin J, Ferry D, Fuchs CS, Petrylak DP, Chau I. (2019) Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncol. 20, 1109-1123. [PMID: 31301962]

Mitxelena J, Apraiz A, Vallejo-Rodríguez J, García-Santisteban I, Fullaondo A, Alvarez-Fernández M, Malumbres M, Zubiaga AM. (2019) An E2F7-dependent transcriptional program modulates DNA damage repair and genomic stability.  Nucleic Acids Res. doi: 10.1093/nar/gkz587. [PMID: 31269207]

Marchiò C, Scaltriti M, Ladanyi M, Iafrate AJ, Bibeau F, Dietel M, Hechtman JF, Troiani T, López-Rios F, Douillard JY, Andrè F, Reis-Filho JS. (2019) ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol. 30, 1417-1427. [PMID: 31268127]

Schuler M, Paz-Ares L, Sequist LV, Hirsh V, Lee KH, Wu YL, Lu S, Zhou C, Feng J, Ellis SH, Samuelsen CH, Tang W, Märten A, Ehrnrooth E, Park K, Yang JC. (2019) First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. Lung Cancer 133, 10-19. [PMID: 31200814]

Garmendia I, Pajares MJ, Hermida-Prado F, Ajona D, Bértolo C, Sainz C, Lavín A, Remírez AB, Valencia K, Moreno H, Ferrer I, Behrens C, Cuadrado M, Paz-Ares L, Bustelo XR, Gil-Bazo I, Alameda D, Lecanda F, Calvo A, Felip E, Sánchez-Céspedes M, Wistuba II, Granda-Diaz R, Rodrigo JP, García-Pedrero JM, Pio R, Montuenga LM, Agorreta J. (2019) YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib. Am J Respir Crit Care Med. 200, 888-899. [PMID: 31166114]

Banuelos-Sanchez G, Sanchez L, Benitez-Guijarro M, Sanchez-Carnerero V, Salvador-Palomeque C, Tristan-Ramos P, Benkaddour-Boumzaouad M, Morell S, Garcia-Puche JL, Heras SR, Franco-Montalban F, Tamayo JA, Garcia-Perez JL. (2019) Synthesis and Characterization of Specific Reverse Transcriptase Inhibitors for Mammalian LINE-1 Retrotransposons. Cell Chem Biol. doi: 10.1016/j.chembiol.2019.04.010. [           PMID: 31155508]

Quintanal-Villalonga A, Ferrer I, Molina-Pinelo S, Paz-Ares L. (2019) A patent review of FGFR4 selective inhibition in cancer (2007-2018). Expert Opin Ther Pat. 29, 429-438. [PMID: 31146605]

Ucero AC, Bakiri L, Roediger B, Suzuki M, Jimenez M, Mandal P, Braghetta P, Bonaldo P, Paz-Ares L, Fustero-Torre C, Ximenez-Embun P, Hernandez AI, Megias D, Wagner EF. (2019) Fra-2-expressing macrophages promote lung fibrosis in mice. J Clin Invest. 129, 3293-3309. [PMID: 31135379]

Sato RH, Kosaka PM, Omori ÁT, Ferreira EA, Petri DFS, Malvar Ó, Domínguez CM, Pini V, Ahumada Ó, Tamayo J, Calleja M, Cunha RLOR, Fiorito PA. (2019) Development of a methodology for reversible chemical modification of silicon surfaces with application in nanomechanical biosensors. Biosens Bioelectron 137 287-293. [PMID: 31125818]

Park K, Bennouna J, Boyer M, Hida T, Hirsh V, Kato T, Lu S, Mok T, Nakagawa K, O’Byrne K, Paz-Ares L, Schuler M, Sibilot DM, Tan EH, Tanaka H, Wu YL, Yang JC, Zhang L, Zhou C, Märten A, Tang W, Yamamoto N. (2019) Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. Lung Cancer 132, 126-131. [PMID: 31097085]

Quintanal-Villalonga A, Molina-Pinelo S, Yagüe P, Marrugal Á, Ojeda-Márquez L, Suarez R, Ponce-Aix S, Enguita AB, Carnero A, Ferrer I, Paz-Ares L. (2019) FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective. Lung Cancer 131, 112-121. [PMID: 31027687]

Putora PM, Glatzer M, De Ruysscher D, Faivre-Finn C, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadiuszko R, Felip E, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, Brien MO, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, Slotman BJ. (2019) Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiother Oncol 135, 74-77. [PMID: 31015173]

Tomás-Loba A, Manieri E, González-Terán B, Mora A, Leiva-Vega L, Santamans AM, Romero-Becerra R, Rodríguez E, Pintor-Chocano A, Feixas F, López JA, Caballero B, Trakala M, Blanco O, Torres JL, Hernández-Cosido L, Montalvo-Romeral V, Matesanz N, Roche-Molina M, Bernal JA, Mischo H, León M, Caballero A, Miranda-Saavedra D, Ruiz-Cabello J, Nevzorova YA, Cubero FJ, Bravo J, Vázquez J, Malumbres M, Marcos M, Osuna S, Sabio G. (2019) p38gamma is essential for cell cycle progression and liver tumourigenesis. Nature 568, 557-560. [PMID: 30971822][Full text][*iLUNG]

Blasco MT, Navas C, Martín-Serrano G, Graña-Castro O, Lechuga CG, Martın-Diaz L, Djurec, M, L, J, Morales-Cacho L, Esteban-Burgos L, Perales-Patón J, Bousquet-Mur E, Castellano E, Jacob HK., Cabras L, Musteanu M, Drosten M, Ortega S, Mulero F, Sainz B, Dusetti N, Iovanna J, Sánchez-Bueno F, Hidalgo M, Khiabanian H, Rabadán R, Al-Shahrour F, Guerra G, Barbacid M. (2019) Complete regression of advanced pancreatic ductal adenocarcinomas upon combined inhibition of EGFR and c-Raf. Cancer Cell 35, 573-587 [PMID: 30975481] [Full text]

Putora PM, Glatzer M, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadziuszko R, Felip E, Faivre-Finn C, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, O’Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Slotman B, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, De Ruysscher D. (2019) Radiother Oncol. 133, 163-166. [PMID: 30935574][Full text]

López-Nieva P, Fernández-Navarro P, Graña-Castro O, Andrés-León E, Santos J, Villa-Morales M, Cobos-Fernández MÁ, González-Sánchez L, Malumbres M, Salazar-Roa M, Fernández-Piqueras J. (2019) Detection of novel fusion-transcripts by RNA-Seq in T-cell lymphoblastic lymphoma. Sci Rep. 9, 5179. [PMID: 30914738][Full text]

Sternberg CN, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Banna GL, De Giorgi U, Masini C, Bamias A, Garcia Del Muro X, Duran I, Powles T, Gamulin M, Zengerling F, Geczi L, Gedye C, de Ducla S, Fear S, Merseburger AS. (2019) Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. Eur Urol. Mar 22. pii: S0302-2838(19)30201-5. [PMID: 30910346][Full text]

Levy B, Paz-Ares L, Bennouna J, Felip E, Abreu DR, Isla D, Barlesi F, Molinier O, Madelaine J, Audigier-Valette C, Kim SW, Kim HR, Ozguroglu M, Erman M, Badin FB, Mekhail TM, Scheff R, Chisamore MJ, Sadrolhefazi B, Riess JW. (2019) Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. Clin Lung Cancer. 108, 120-128. [PMID: 30808583][Full text]

Büttner R, Longshore JW, López-Ríos F, Merkelbach-Bruse S, Normanno N, Rouleau E, Penault-Llorca F. (2019) Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO Open 4, e000442. [PMID: 30792906][Full text]

Ready N, Hellmann MD, Awad MM, Otterson GA, Gutierrez M, Gainor JF, Borghaei H, Jolivet J, Horn L, Mates M, Brahmer J, Rabinowitz I, Reddy PS, Chesney J, Orcutt J, Spigel DR, Reck M, O’Byrne KJ, Paz-Ares L, Hu W, Zerba K, Li X, Lestini B, Geese WJ, Szustakowski JD, Green G, Chang H, Ramalingam SS. (2019) First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. J. Clin. Oncol. 37, 992-1000. [PMID: 30785829][Full text]

Schuler M, Tan EH, O’Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Massey D, Märten A, Paz-Ares L, Park K. (2019) First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. J. Cancer Res. Clin. Oncol. 145, 1569-1579. [PMID:30783814][Full text]

Bustos-Morán, E., Blas-Rus, N., Alcaraz-Serna, A., Iborra, S., González-Martínez, J., Malumbres, M., Sánchez-Madrid, F. (2019) Aurora A controls CD8+ T cell cytotoxic activity and antiviral response. Sci. Rep. 9, 2211. [PMID:30778113][Full text]

Quintanal-Villalonga A, Molina-Pinelo S, Yagüe P, Marrugal A, Ojeda-Márquez L, Suarez R, Ponce-Aix S, Enguita AB, Carnero A, Ferrer I*, Paz-Ares L*. (2019) FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective. Lung Cancer, in press. [*iLUNG]

Reck M, Kerr KM, Grohé C, Manegold C, Pavlakis N, Paz-Ares L, Huber RM, Popat S, Thatcher N, Park K, Hilberg F, Barrueco J, Kaiser R. (2019) Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity? Future Oncol. 15, 1363-1383 [PMID:30758227]

Vázquez-Domínguez, I., González-Sánchez, L., López-Nieva, P., Fernández-Navarro, P., Villa-Morales, M., Cobos-Fernández, M.A, Sastre, I., Fraga, M.F., Fernández, A.F., Malumbres, M., Salazar-Roa, M., Graña-Castro, O., Santos, J., Llamas, P., López-Lorenzo, J.L., Fernández-Piqueras, J. (2019) Downregulation of specific FBXW7 isoforms with differential effects in T-cell lymphoblastic lymphoma. Oncogene 38, 4620-4636. [PMID:30742097][Full text]

Manso L, Moreno Antón F, Izarzugaza Perón Y, Delgado Mingorance JI, Borrega García P, Echarri González MJ, Martínez-Jañez N, López-González A, Olier Garate C, Ballesteros García A, Chacón López-Muñíz I, Ciruelos Gil E, García-Sáenz JA, Paz-Ares L. (2019) Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study. Breast J., 25, 219-225.  [PMID:30734437]

Levy BP, Giaccone G, Besse B, Felip E, Garassino MC, Domine Gomez M, Garrido P, Piperdi B, Ponce-Aix S, Menezes D, MacBeth KJ, Risueño A, Slepetis R, Wu X, Fandi A, Paz-Ares L. (2019) Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. Eur. J. Cancer. 108, 120-128 [PMID:30654297]

Quintanal-Villalonga A, Molina-Pinelo S, Cirauqui C, Ojeda-Márquez L, Marrugal Á, Suarez R, Conde E, Ponce-Aix S, Enguita AB, Carnero A, Ferrer I*, Paz-Ares L*. (2019) FGFR1 cooperates with EGFR in lung cancer oncogenesis, and their combined inhibition shows improved efficacy. J. Thorac. Oncol. Jan 9. pii: S1556-0864(19)30008-5. [PMID:30639621] [*iLUNG]

Peters S, Dafni U, Boyer M, De Ruysscher D, Faivre-Finn C, Felip E, Garrido P, Girard N, Guckenberger M, Haanen J, Le Pechoux C, Mornex F, Ozsahin M, Paz-Ares L, Planchard D, Raben D, Ramalingam S, Reck M, Smit E, Stahel R, Stenzinger A, Swanton C, Vallone S, Garassino M. (2019) Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Ann. Oncol. 30, 161-165.. [PMID:30624547]

Thatcher N, Goldschmidt JH, Thomas M, Schenker M, Pan Z, Paz-Ares L, Breder V, Ostoros G, Hanes V. (2019) Efficacy & Safety of Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Non-small Cell Lung Cancer(MAPLE):A Randomized,Double-blind,Phase 3 Study. Clin. Cancer Res. Jan 7. pii: clincanres.2702.2018. [PMID:30617139]

Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, Beasley MB, Thunnissen E, Pelosi G, Rekhtman N, Bubendorf L, Mino-Kenudson M, Yoshida A, Geisinger KR, Noguchi M, Chirieac LR, Bolting J, Chung JH, Chou TY, Chen G, Poleri C, Lopez-Rios F, Papotti M, Sholl LM, Roden AC, Travis WD, Hirsch FR, Kerr KM, Tsao MS, Nicholson AG, Wistuba I, Moreira AL. (2019) Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. J Thorac Oncol. 14, 377-407. [PMID: 30572031]

Yao Z, Gao Y, Su W, Yaeger R, Tao J, Na N, Zhang Y, Zhang C, Rymar A, Tao A, Timaul NM, Mcgriskin R, Outmezguine NA, Zhao H, Chang Q, Qeriqi B, Barbacid M, de Stanchina E, Hyman DM, Bollag G, Rosen N. (2019) RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nat. Med. 25, 284-291. [PMID:30559419][Full text]

Zugazagoitia J, Ramos I, Trigo JM, Palka M, Gómez-Rueda A, Jantus-Lewintre E, Camps C, Isla D, Iranzo P, Ponce-Aix S, García-Campelo R, Provencio M, Franco F, Bernabé R, Juan-Vidal O, Felip E, de Castro J, Sanchez-Torres JM, Faul I, Lanman RB, Garrido P, Paz-Ares L. (2019) Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. Ann Oncol. 30, 290-296. [PMID: 30535340]

Díaz-Serrano A, Sánchez-Torre A, Paz-Ares L. (2019) Necitumumab for the treatment of advanced non-small-cell lung cancer. Future Oncol. 15, 705-716. [PMID: 30501503]

Patel JD, Paz-Ares L, Zinner RG, Barlesi F, Koustenis AG, Obasaju CK. (2019) Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care. Clin Lung Cancer 19, e823-e830. [PMID: 30369427]

Farago AF, Drapkin BJ, Lopez-Vilarino de Ramos JA, Galmarini CM, Núñez R, Kahatt C, Paz-Ares L. (2019) ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line. Future Oncol. 15, 231-239. [PMID:30362375]

Sorbye H, Baudin E, Borbath I, Caplin M, Chen J, Cwikla JB, Frilling A, Grossman A, Kaltsas G, Scarpa A, Welin S, Garcia-Carbonero R; ENETS 2016 Munich Advisory Board Participants. (2019) Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). Neuroendocrinology 108, 54-62. [PMID: 30153658]

Malumbres M. (2019) CDK4/6 Inhibitors: What Is the Best Cocktail? Clin. Cancer Res. 25, 6-8. [PMID:30115629] [*iLUNG]

Redondo B, Moliz C, Alonso M, Paz-Ares L, Praga M, Morales E. (2019) Cancer immunotherapy: Great expectations in the world of oncology but a cause for kidney concern. Nefrologia 39, 94-96. [PMID:29941195]

Spicer J, Provencio M, Garrido Lopez P, Bosch-Barrera J, de Castro Carpeño FJ, Felip E, Trigo J, Viteri S, Coart E, Schmidt E, Christiansen AV, Zocca MB, Andersen MH, Ehrnrooth E, Paz-Ares L. (2019) An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer. Ann Oncol. doi: 10.1093/annonc/mdz063.078.

Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, Beasley MB, Thunnissen E, Pelosi G, Rekhtman N, Bubendorf L, Mino-Kenudson M, Yoshida A, Geisinger KR, Noguchi M, Chirieac LR, Bolting J, Chung JH, Chou TY, Chen G, Poleri C, Lopez-Rios F, Papotti M, Sholl LM, Roden AC, Travis WD, Hirsch FR, Kerr KM, Tsao MS, Nicholson AG, Wistuba I, Moreira AL. (2018) Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. J Thorac Oncol. Dec. 7, pii: S1556-0864(18)33514-7. [PMID:30572031]

Yao Z, Gao Y, Su W, Yaeger R, Tao J, Na N, Zhang Y, Zhang C, Rymar A, Tao A, Timaul NM, Mcgriskin R, Outmezguine NA, Zhao H, Chang Q, Qeriqi B, Barbacid M, de Stanchina E, Hyman DM, Bollag G, Rosen N. (2018) RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nat Med. Dec. 17, doi: 10.1038/s41591-018-0274-5. [PMID:30559419]

Zugazagoitia J, Ramos I, Trigo JM, Palka M, Gómez-Rueda A, Jantus-Lewintre E, Camps C, Isla D, Iranzo P, Ponce-Aix S, García-Campelo R, Provencio M, Franco F, Bernabé R, Juan-Vidal O, Felip E, de Castro J, Sanchez-Torres JM, Faul I, Lanman RB, Garrido P, Paz-Ares L. (2018) Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. Ann Oncol. Dec. 10, doi: 10.1093/annonc/mdy512. [PMID:30535340]

Díaz-Serrano A, Sánchez-Torre A, Paz-Ares L. (2018) Necitumumab for the treatment of advanced non-small-cell lung cancer. Future Oncol., Dec. 3, doi: 10.2217/fon-2018-0594. [PMID:30501503]

González Rubio S, Montero Pastor N, García C, Almendro-Vedia VG, Ferrer I, Natale P, Paz-Ares L, Lillo MP, López-Montero I. (2018) Enhanced Cytotoxic Activity of Mitochondrial Mechanical Effectors in Human Lung Carcinoma H520 Cells: Pharmaceutical Implications for Cancer Therapy. Front Oncol. 8, 514. [PMID:30483474]

Rata S, Suarez Peredo Rodriguez MF, Joseph S, Peter N, Echegaray Iturra F, Yang F, Madzvamuse A, Ruppert JG, Samejima K, Platani M, Alvarez-Fernandez M, Malumbres M, Earnshaw WC, Novak B, Hochegger H. (2018) Two Interlinked Bistable Switches Govern Mitotic Control in Mammalian Cells. Curr Biol. 28, 3824-3832. [PMID:30449668]

Nguyen AL, Drutovic D, Vazquez BN, El Yakoubi W, Gentilello AS, Malumbres M, Solc P, Schindler K. (2018) Genetic Interactions between the Aurora Kinases Reveal New Requirements for AURKB and AURKC during Oocyte Meiosis. Curr Biol. 28, 3458-3468. [PMID:30415701]

Patel JD, Paz-Ares L, Zinner RG, Barlesi F, Koustenis AG, Obasaju CK. (2018) Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care. Clin Lung Cancer 19, e823-e830. [PMID:30369427]

Muñoz-Unceta N, Burgueño I, Jiménez E, Paz-Ares L. (2018) Durvalumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 10, 17588359-18804151. [PMID:30344651]

Ramos D, Malvar O, Davis ZJ, Tamayo J, Calleja M. (2018) Nanomechanical Plasmon Spectroscopy of Single Gold Nanoparticles. Nano Lett. Oct 19. doi: 10.1021/acs.nanolett.8b03236. [PMID:30339403]

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH,de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M;PACIFIC Investigators. (2018) Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 379, 2342-2350. [PMID:30280658]

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, CsősziT, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. (2018) Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.  N Engl J Med. 379, 2040-2051. [PMID:30280635]

Ferrer I, Zugazagoitia J, Herbertz S, John W, Paz-Ares L, Schmid-Bindert G. (2018) KRAS-Mutant non-small cell lung cancer: From biology to therapy.  Lung Cancer. 124, 53-64. [PMID:30268480]

Hurtado B, Trakala M, Ximénez-Embún P, El Bakkali A, Partida D, Sanz-Castillo B, Álvarez-Fernández M, Maroto M, Sánchez-Martínez R, Martínez L, Muñoz J, García de Frutos P, Malumbres M. (2018) Thrombocytopenia-associated mutations in Ser/Thr kinase MASTL deregulate actin cytoskeleton dynamics in platelets. J Clin Invest. 128, 5351-5367. [PMID:30252678]

Cabillic F, Hofman P, Ilie M, Peled N, Hochmair M, Dietel M, Von Laffert M, Gosney JR, Lopez-Rios F, Erb G, Schalles U, Barlesi F. (2018) ALK IHC and FISH discordant results in patients with NSCLC and treatment response: for discussion of the question-to treat or not to treat? ESMO Open. 3, e000419. [PMID:30245863]

Hellmann MD, Paz-Ares L. (2018) Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 379, 1093-1094. [PMID:30207915]

Sonntag R, Giebeler N, Nevzorova YA, Bangen JM, Fahrenkamp D, Lambertz D, Haas U, Hu W, Gassler N, Cubero FJ, Müller-Newen G, Abdallah AT, Weiskirchen R, Ticconi F, Costa IG, Barbacid M, Trautwein C, Liedtke C. (2018) Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma. Proc Natl Acad Sci U S A 115, 9282-9287. [PMID:30150405]

Ferrer I, Quintanal-Villalonga Á, Molina-Pinelo S, Garcia-Heredia JM, Perez M, Suárez R, Ponce-Aix S, Paz-Ares L, Carnero A. (2018) MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma. J Exp Clin Cancer Res. 37, 195. [PMID:30119639]

Ovejero S, Ayala P, Malumbres M, Pimentel-Muiños FX, Bueno A, Sacristán MP. (2018) Biochemical analyses reveal amino acid residues critical for cell cycle-dependent phosphorylation of human Cdc14A phosphatase by cyclin-dependent kinase 1. Sci Rep. 8, 11871. [PMID:30089874]

Kim ES, Kelly K, Paz-Ares LG, Garrido P, Jalal S, Mahadevan D, Gutierrez M, Provencio M, Schaefer E, Shaheen M, Johnston EL, Turner PK, Kambhampati SRP, Beckmann R, Hossain A, John WJ, Goldman JW. (2018) Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. Clin Cancer Res. 24, 5543-5551. [PMID:30082474]

de Cárcer G, Venkateswaran SV, Salgueiro L, El Bakkali A, Somogyi K, Rowald K, Montañés P, Sanclemente M, Escobar B, de Martino A, McGranahan N, Malumbres M, Sotillo R. (2018) Plk1 overexpression induces chromosomal instability and suppresses tumor development. Nat Commun. 9, 3012. [PMID:30069007]

Cussó L, Musteanu M, Mulero F, Barbacid M, Desco M. (2018) Effects of a Ketogenic Diet on [18F]FDG-PET Imaging in a Mouse Model of Lung Cancer. Mol Imaging Biol. Jul 2. doi: 10.1007/s11307-018-1233-8. [PMID:29968182]

de Marinis F, Ciardiello F, Baas P, Crinò L, Giaccone G, Grossi F, Hellmann MD, Mok TSK, Lena H, Paz-Ares L, Rodriguez-Abreu D, Von Pavel J, Gridelli C. (2018) 30 Immunotherapy in advanced NSCLC-from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). ESMO Open 3, e000298. [PMID:29942662]

Moll HP, Pranz K, Musteanu M, Grabner B, Hruschka N, Mohrherr J, Aigner P, Stiedl P, Brcic L, Laszlo V, Schramek D, Moriggl R, Eferl R, Moldvay J, Dezso K, Lopez-Casas PP, Stoiber D, Hidalgo M, Penninger J, Sibilia M, Győrffy B, Barbacid M, Dome B, Popper H, Casanova E. (2018) Afatinib restrains K-RAS-driven lung tumorigenesis. Sci Transl Med. 10, pii: eaao2301. [PMID:29925635]

Bonomi PD, Gandara D, Hirsch FR, Kerr KM, Obasaju C, Paz-Ares L, Bellomo C, Bradley JD, Bunn PA Jr, Culligan M, Jett JR, Kim ES, Langer CJ, Natale RB, Novello S, Pérol M, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Vansteenkiste JF, Wakelee H, Thatcher N. (2018) Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. Ann Oncol. 29, 1701-1709. [PMID:29905778]

Bellutti F, Tigan AS, Nebenfuehr S, Dolezal M, Zojer M, Grausenburger R, Hartenberger S, Kollmann S, Doma E, Prchal-Murphy M, Uras IZ, Höllein A, Neuberg DS, Ebert BL, Ringler A, Mueller AC, Loizou JI, Hinds PW, Vogl C, Heller G, Kubicek S, Zuber J, Malumbres M, Farlik M, Villunger A, Kollmann K, Sexl V. (2018) CDK6 Antagonizes p53-Induced Responses during Tumorigenesis. Cancer Discov. 8, 884-897. [PMID:29899063]

Young K, Paz-Ares L, Thatcher N, Spigel DR, Shahidi J, Soldatenkova V, Grau G, Kurek R, Shepherd FA. (2018) Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis. Thromb Res. 167, 50-56. [PMID:29787943]

Hirsch FR, Kerr KM, Bunn PA Jr, Kim ES, Obasaju C, Pérol M, Bonomi P, Bradley JD, Gandara D, Jett JR, Langer CJ, Natale RB, Novello S, Paz-Ares L, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Stinchcombe TE, Vansteenkiste JF, Wakelee H, Thatcher N. (2018) Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. Clin Lung Cancer 19, 331-339. [PMID:29773328]

Quintanal-Villalonga Á, Mediano M, Ferrer I, Meléndez R, Carranza-Carranza A, Suárez R, Carnero A, Molina-Pinelo S, Paz-Ares L. (2018) Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer. Oncotarget 9, 19945-19960. [PMID:29731995]

Keppens C, Palma JF, Das PM, Scudder S, Wen W, Normanno N, van Krieken JH, Sacco A, Fenizia F, Gonzalez de Castro D, Hönigschnabl S, Kern I, Lopez-Rios F, Lozano MD, Marchetti A, Halfon P, Schuuring E, Setinek U, Sorensen B, Taniere P, Tiemann M, Vosmikova H, Dequeker EMC. (2018) Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe. J Mol Diagn. 20, 483-494. [PMID:29704571]

Díaz-Serrano A, Angulo B, Dominguez C, Pazo-Cid R, Salud A, Jiménez-Fonseca P, Leon A, Galan MC, Alsina M, Rivera F, Plaza JC, Paz-Ares L, Lopez-Rios F, Gómez-Martín C. (2018) Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab. Oncologist 23, 1092-1102. [PMID:29700210]

López-Nieva P, Fernández-Navarro P, Vaquero-Lorenzo C, Villa-Morales M, Graña-Castro O, Cobos-Fernández MÁ, López-Lorenzo JL, Llamas P, González-Sanchez L, Sastre I, Pollan M, Malumbres M, Santos J, Fernández-Piqueras J. (2018) RNA-Seq reveals the existence of a CDKN1C-E2F1-TP53 axis that is altered in human T-cell lymphoblastic lymphomas. BMC Cancer 18, 430. [PMID:29661169]

Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O’Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F, Paz-Ares L. (2018) Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 378, 2093-2104. [PMID:29658845]

Wu YL, Sequist LV, Tan EH, Geater SL, Orlov S, Zhang L, Lee KH, Tsai CM, Kato T, Barrios CH, Schuler M, Hirsh V, Yamamoto N, O’Byrne K, Boyer M, Mok T, Peil B, Märten A, Chih-Hsin Yang J, Paz-Ares L, Park K. (2018) Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. Clin Lung Cancer 19, e465-e479. [PMID:29653820]

Mayor-Ruiz C, Olbrich T, Drosten M, Lecona E, Vega-Sendino M, Ortega S, Dominguez O, Barbacid M, Ruiz S, Fernandez-Capetillo O. (2018) ERF deletion rescues RAS deficiency in mouse embryonic stem cells. Genes Dev. 32, 568-576. [PMID:29650524]

Mitxelena J, Apraiz A, Vallejo-Rodríguez J, García-Santisteban I, Fullaondo A, Alvarez-Fernández M, Malumbres M, Zubiaga AM. (2018) An E2F7-dependent transcriptional program modulates DNA damage repair and genomic stability. Nucleic Acids Res. 46, 4546-4559. [PMID:29590434]

Simón-Carrasco L, Jiménez G, Barbacid M, Drosten M. (2018) The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer. Cell Cycle 17, 702-711. [PMID:29578365]

Zugazagoitia J, Biosca M, Oliveira J, Olmedo ME, Dómine M, Nadal E, Ruffinelli JC, Muñoz N, Luna AM, Hernández B, Martínez M, Gallego I, Martínez de Castro E, Font C, Calvo V, Martínez-Marín V, Corral J, Noguerón E, Mondéjar R, García Escobar I, Salvador-Coloma C, Juan Ó, Sánchez Cánovas M, Valdivia J, Ochoa MP, López Castro R, Obispo B, Pangua C, Sereno M, Fernández Franco L, Mielgo X, Calzas J, Blasco A, Aparisi F, Chara L, Grau JF, Soares M, Gómez A, Zenzola V, García-Morillo M, Cacho D, Díaz-Serrano A, Aguado C, Ponce-Aix S, González-Larriba JL, Muñoz AJ, Lora D, Paz-Ares L, Manzano A. (2018) Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer. Eur Respir J. 5, pii: 1702431. [PMID:29563169]

Block MS, Vierkant RA, Rambau PF, Winham SJ, Wagner P, Traficante N, Tołoczko A, Tiezzi DG, Taran FA, Sinn P, Sieh W, Sharma R, Rothstein JH, Ramón Y Cajal T, Paz-Ares L, Oszurek O, Orsulic S, Ness RB, Nelson G, Modugno F, Menkiszak J, McGuire V, McCauley BM, Mack M, Lubiński J, Longacre TA, Li Z, Lester J, Kennedy CJ, Kalli KR, Jung AY, Johnatty SE, Jimenez-Linan M, Jensen A, Intermaggio MP, Hung J, Herpel E, Hernandez BY, Hartkopf AD, Harnett PR, Ghatage P, García-Bueno JM, Gao B, Fereday S, Eilber U, Edwards RP, de Sousa CB, de Andrade JM, Chudecka-Głaz A, Chenevix-Trench G, Cazorla A, Brucker SY; Australian Ovarian Cancer Study Group, Alsop J, Whittemore AS, Steed H, Staebler A, Moysich KB, Menon U, Koziak JM, Kommoss S, Kjaer SK, Kelemen LE, Karlan BY, Huntsman DG, Høgdall E, Gronwald J, Goodman MT, Gilks B, García MJ, Fasching PA, de Fazio A, Deen S, Chang-Claude J, Candido Dos Reis FJ, Campbell IG, Brenton JD, Bowtell DD, Benítez J, Pharoah PDP, Köbel M, Ramus SJ, Goode EL. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc. 93, 307-320. [PMID:29502561]

Carretero-González A, Lora D, Ghanem I, Zugazagoitia J, Castellano D, Sepúlveda JM, López-Martin JA, Paz-Ares L, de Velasco G. (2018) Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials. Oncotarget 9, 8706-8715. [PMID:29492229]

Gao Y, Chang MT, McKay D, Na N, Zhou B, Yaeger R, Torres NM, Muniz K, Drosten M, Barbacid M, Caponigro G, Stuart D, Moebitz H, Solit DB, Abdel-Wahab O, Taylor BS, Yao Z, Rosen N. (2018) Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Cancer Discov. 8, 648-661. [PMID:29483135]

Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. (2018) Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 29(suppl_1), i10-i19. [PMID:29462254]

Middleton G, Gridelli C, De Marinis F, Pujol JL, Reck M, Ramlau R, Parente B, Pieters T, Visseren-Grul CM, San Antonio B, John WJ, Zimmermann AH, Chouaki N, Paz-Ares L. (2018) Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Curr Med Res Opin. 34, 865-871. [PMID:29424248]

Quintanal-Villalonga Á, Ojeda-Márquez L, Marrugal Á, Yagüe P, Ponce-Aix S, Salinas A, Carnero A, Ferrer I, Molina-Pinelo S, Paz-Ares L. (2018) The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction. Sci Rep. 8, 2394. [PMID:29402970]

Gridelli C, Baas P, Barlesi F, Ciardiello F, Crinò L, Felip E, Gadgeel S, Papadimitrakopoulou V, Paz-Ares L, Planchard D, Perol M, Hanna N, Sgambato A, Casaluce F, de Marinis F. (2018) Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer 19, 301-314. [PMID:29396237]

Sanclemente M, Francoz S, Esteban-Burgos L, Bousquet-Mur E, Djurec M, Lopez-Casas PP, Hidalgo M, Guerra C, Drosten M, Musteanu M, Barbacid M. (2018) c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling. Cancer Cell 33, 217-228.e4. [PMID:29395869]

Djurec M, Graña O, Lee A, Troulé K, Espinet E, Cabras L, Navas C, Blasco MT, Martín-Díaz L, Burdiel M, Li J, Liu Z, Vallespinós M, Sanchez-Bueno F, Sprick MR, Trumpp A, Sainz B Jr, Al-Shahrour F, Rabadan R, Guerra C, Barbacid M. (2018) Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors. Proc Natl Acad Sci U S A 115, E1147-E1156. [PMID:29351990]

Reck M, Garon EB, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Kiura K, Widau RC, He S, Dalal R, Lee P, Nakagawa K. (2018) Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. Clin Lung Cancer 19, 213-220.e4. [PMID:29317191]

Álvarez-Fernández M, Sanz-Flores M, Sanz-Castillo B, Salazar-Roa M, Partida D, Zapatero-Solana E, Ali HR, Manchado E, Lowe S, VanArsdale T, Shields D, Caldas C, Quintela-Fandino M, Malumbres M. (2018) Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer. Cell Death Differ. 25, 828-840. [PMID:29229993]

Domínguez CM, Ramos D, Mingorance J, Fierro JLG, Tamayo J, Calleja M. (2018) Direct Detection of OXA-48 Carbapenemase Gene in Lysate Samples through Changes in Mechanical Properties of DNA Monolayers upon Hybridization. Anal Chem. 90, 968-973. [PMID:29186953]

Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn PA Jr, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Wakelee H, Thatcher N. (2018) Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. J Thorac Oncol. 13, 165-183. [PMID:29175116]

Genova C, Socinski MA, Hozak RR, Mi G, Kurek R, Shahidi J, Paz-Ares L, Thatcher N, Rivard CJ, Varella-Garcia M, Hirsch FR. (2018) EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study. J Thorac Oncol. 13, 228-236. [PMID:29158193]

Ciuleanu T, Socinski MA, Obasaju C, Luft AV, Szczesna A, Szafrański W, Ramlau R, Bálint B, Molinier O, Depenbrock H, Nanda S, Paz-Ares L, Thatcher N. (2018) Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer. Clin Lung Cancer 19, 130-138.e2. [PMID:29158123]

Kosaka PM, Calleja M, Tamayo J. (2018) Optomechanical devices for deep plasma cancer proteomics. Semin Cancer Biol. 52, 26-38. [PMID:28867489]

Conde E, Caminoa A, Dominguez C, Calles A, Walter S, Angulo B, Sánchez E, Alonso M, Jimenez L, Madrigal L, Hernando F, Sanz-Ortega J, Jimenez B, Garrido P, Paz-Ares L, de Castro J, Hernandez S, Lopez-Rios F. 2018. Aligning digital CD8+ scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma. Histopathology. 72, 270-284. [PMID:28815764]

Zugazagoitia J, Rueda D, Carrizo N, Enguita AB, Gómez-Sánchez D, Díaz-Serrano A, Jiménez E, Mérida A, Calero R, Lujan R, De Miguel E, Gámez P, Díaz-Hellín V, Nuñez JA, Iglesias L, Ferrer I, Paz-Ares L, Ponce-Aix S. (2018) Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments. Clin Lung Cancer. 19, 65-73.e7. [PMID:28780976]

Drosten M, Guerra C, Barbacid M. (2018) Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets. Cold Spring Harb Perspect Med. 8, (5) pii: a031542. [PMID:28778964]

Díaz-Serrano A, Gella P, Jiménez E, Zugazagoitia J, Paz-Ares Rodríguez L. (2018) Targeting EGFR in Lung Cancer: Current Standards and Developments. Drugs. Jun 18. doi: 10.1007/s40265-018-0916-4 [PMID:29915896]